X0202 SCHEDULE 13G/A 0000902664-25-003592 0001784547 XXXXXXXX LIVE 3 Common Stock, par value $0.001 per share 06/30/2026 0001819133 Tango Therapeutics, Inc. 87583X109 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 Rule 13d-1(b) Woodline Partners LP DE 4000567.00 0.00 4000567.00 0.00 4000567.00 N 2.5 IA PN Tango Therapeutics, Inc. 201 Brookline Ave., Suite 901, Boston, MA 02215 This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP (together, the "Woodline Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Tango Therapeutics, Inc. (the "Company") directly held by the Woodline Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein. The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. Woodline Partners is a Delaware limited partnership. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 162,814,649 shares of Common Stock outstanding, which is the sum of (i) the 18,166,667 shares of Common Stock offered pursuant to the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the "SEC") on June 10, 2026 and (ii) the 144,647,982 shares of Common Stock outstanding as of May 6, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 filed with the SEC on May 13, 2026. 2.5% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. N Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Woodline Partners LP /s/ Erin Mullen 08/14/2026